Health economics of market access for biopharmaceuticals and biosimilars

Journal of Medical Economics

Volumn 12, Issue 3, 2009, Pages 211-218

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biopharmaceutical; Biosimilar; Health economics; Pricing; Registration; Reimbursement; Research and development

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ALGLUCERASE; ALPHA INTERFERON; ALTEPLASE; BASILIXIMAB; BETA INTERFERON; BIOLOGICAL MARKER; BIOSIMILAR DRUG; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHOLERA VACCINE; DACLIZUMAB; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILGRASTIM RATIOPHARM; GAMMA INTERFERON; GENERIC DRUG; HEPATITIS B SURFACE ANTIGEN; HUMAN GROWTH HORMONE; IMIGLUCERASE; INSULIN ASPART; RATIOGRASTIM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RETEPLASE; TENECTEPLASE; TEVAGRASTIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOTECHNOLOGY; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; NOTE; PROSPECTIVE PRICING; REGISTRATION; REIMBURSEMENT;

BIOLOGICAL PRODUCTS; BIOMEDICAL RESEARCH; BIOPHARMACEUTICS; DRUG COSTS; DRUGS, GENERIC; HUMANS; PRESCRIPTION FEES;

EID: 75149181512     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903260094     Document Type: Note

References (40)

1. Young FE. Biotechnology: the view from the FDA. Health Matrix 1986;4:10-15.
2. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care 2003;9:S124-135.
3. IMS Health. IMS lifecycle R&D focus. London: IMS Health, 2007
4. Simon F. Market access for biopharmaceuticals: new challenges. Health Aff (Millwood) 2006;25:1363-1370
5. IMS Health. IMS MIDAS Therapy forecaster, market insights. London: IMS Health, 2006.
6. Cohen M, Morrow T, Penna P. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies. Am J Manag Care 2006;12:S24-37.
7. Staginnus U. Health economics in the era of biologics. London 2008.
8. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-419
9. Oldham T. Strategies for entering the biosimilar market. In: Biosimilars - Evolution or Revolution? London: Biopharm Knowledge Publishing, 2006.
10. DiMasi J, Grabowski H. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 2007;28:469-479
11. Mathieu M. Parexel's pharmaceutical R&D Statistical Sourcebook 2004/2005. Waltham, MA: Parexel, 2004.
12. Grabowski H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 2008;7:479-488
13. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-185
14. European Commission. Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal of the European Union 2004;1(L 136/1 - L 136/33).
15. European Generic Medicines Association. EGA Handbook on Biosimilar Medicines. Brussels: European Generic Medicines Association, 2008.
16. European Medicines Agency. European Public Assessment Report of Trastuzumab - scientific discussion. London: European Medicines Agency, 2005.
17. Schneider CK, Schaffner-Dallmann G. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 2008;7:893-899
18. European Medicines Agency. European Public Assessment Report of Remicade - scientific discussion. London: European Medicines Agency, 2007.
19. European Medicines Agency. European Public Assessment Report of Natalizumab - scientific discussion. London: European Medicines Agency, 2006.
20. European Medicines Agency. Guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products. London: European Medicines Agency, 2008.
21. Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood) 2006;25:1353-1362
22. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007;25:727-734
23. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001;4:225-250
24. Vernon JA, Johnson SJ, Hughen WK, et al. Economic and developmental considerations for pharmacogenomic technology. Pharmacoeconomics 2006;24:335-343
25. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008;26:551-556
26. Barham L. Multiple sclerosis risk-sharing: four years on. Pharma Pricing Reimbursement 2006;11:100-101
27. Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood) 2006;25:1291-1301
28. European Medicines Agency. Guideline on similar biological medicinal products. London: European Medicines Agency, 2006.
29. International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic Guidelines around the World. Lawrenceville, NJ: ISPOR, 2008.
30. Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmacoeconomic evaluations in Belgium. Health technology assessment. Brussels: Belgian Healthcare Knowledge Centre, 2008.
31. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531
32. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300-330
33. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-411
34. Amgen. Neupogen prescribing information. Thousand Oaks, CA: Amgen, 2007.
35. Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 2003;21:1295-1313
36. European Medicines Agency. Assessment report for Filgrastim Ratiopharm. London: European Medicines Agency, 2008.
37. Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10:715-724
38. Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-179
39. Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25:401-411
40. Ramsey S, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009;12:217-225